Advertisement

Factors influencing the use of extended adjuvant endocrine therapy

  • Kunal C. Kadakia
  • Kelley M. Kidwell
  • Debra L. Barton
  • Anne F. Schott
  • Daniel F. Hayes
  • Jennifer J. Griggs
  • N. Lynn HenryEmail author
Clinical trial
  • 37 Downloads

Abstract

Purpose

Extending adjuvant endocrine therapy (ET) beyond 5 years has been shown to improve outcomes in breast cancer; however, limited data are available about if and why women pursue extended ET. The primary objective was to estimate the proportion of women who were willing to receive extended ET if recommended by their physician and secondarily, to determine what factors were associated with this decision.

Methods

This descriptive cross-sectional study surveyed 131 women with AJCC 7th Edition stages I–III breast cancer who had been taking adjuvant ET for 3–5 years. The survey inquired about the willingness to continue ET, quality of life (FACT-ES), and beliefs about medications (BMQ). Logistic regression was used to test for associations between clinical and disease factors, FACT-ES, BMQ, and the primary outcome.

Results

One hundred and twelve (85%) patients reported “moderate” (n = 30, 23%), “quite a bit” (n = 41, 31%), or “extreme” (n = 41, 31%) willingness to pursue extended ET; 19 (14%) patients were “not at all” or were “unlikely” to be willing to take extended ET. On univariate analysis, lower total and social well-being FACT-ES scores, and lower perceived necessity and higher concerns on BMQ were associated with lower willingness to pursue extended ET. On multivariable analysis, greater patient perception of necessity of ET was the only factor associated with willingness to pursue extended ET (OR 1.34, 95% CI 1.15–1.57, p = 0.0005).

Conclusions

Most women who have taken ET for multiple years report being willing to pursue extended ET if recommended. When discussing extended ET, the data from this study support exploring patients’ belief of medication necessity.

Keywords

Aromatase inhibitors Tamoxifen Quality of life Decision making Surveys and questionnaires Drug-related side effects and adverse reactions 

Notes

Author contributions

KCK: Conceptualization, data curation, formal analysis, investigation, methodology, validation, visualization, writing—original draft, review, and editing. KMK: Data curation, formal analysis, methodology, software, and writing—review and editing. DLB: Conceptualization, supervision, and writing—review and editing. JG: Conceptualization, supervision, and writing—review and editing. AFS: Writing—review and editing. DFH: Writing—review and editing. NLH: Conceptualization, data curation, funding acquisition, investigation, project administration, resources, supervision, writing—original draft, review, and editing.

Funding

This study was funded by NLH who was a Damon Runyon-Lilly Clinical Investigator supported (in part) by the Damon Runyon Cancer Research Foundation (Grant Number CI-53-10) and by an American Cancer Society Research Scholar Grant (124654-RSG-13-240-01-PCSM).

Compliance with ethical standards

Conflict of interest

All authors report no conflicts of interest specific to the content of the submitted manuscript. NLH and DFH have conflicts of interest not related to the current manuscript which are documented on the signed Conflict of Interest Disclosure Forms submitted with the manuscript. All authors report no conflicts of interest to disclose.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

10549_2019_5145_MOESM1_ESM.docx (14 kb)
Supplementary material 1 (DOCX 14 KB)
10549_2019_5145_MOESM2_ESM.docx (19 kb)
Supplementary material 2 (DOCX 18 KB)
10549_2019_5145_MOESM3_ESM.docx (32 kb)
Supplementary material 3 (DOCX 32 KB)

References

  1. 1.
    DeSantis CE, Ma J, Goding Sauer A et al (2017) Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin 67:439–448.  https://doi.org/10.3322/caac.21412 CrossRefGoogle Scholar
  2. 2.
    Burstein HJ, Temin S, Anderson H et al (2014) Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. J Clin Oncol 32:2255–2269.  https://doi.org/10.1200/JCO.2013.54.2258 CrossRefGoogle Scholar
  3. 3.
    Burstein HJ, Lacchetti C, Anderson H et al (2016) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. J Clin Oncol 34:1689–1701.  https://doi.org/10.1200/JCO.2015.65.9573 CrossRefGoogle Scholar
  4. 4.
    Gradishar WJ, Anderson BO, Balassanian R et al (2016) Invasive breast cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw 14:324–354CrossRefGoogle Scholar
  5. 5.
    Pan H, Gray R, Braybrooke J et al (2017) 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 377:1836–1846.  https://doi.org/10.1056/NEJMoa1701830 CrossRefGoogle Scholar
  6. 6.
    Gray R, Rea D, Handley K et al (2013) aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6953 women with early breast cancer. J Clin Oncol 31(18 Suppl):5.  https://doi.org/10.1200/jco.2013.31.18_suppl.5 CrossRefGoogle Scholar
  7. 7.
    Davies C, Pan H, Godwin J et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381:805–816.  https://doi.org/10.1016/S0140-6736(12)61963-1 CrossRefGoogle Scholar
  8. 8.
    Mamounas EP, Jeong J-H, Wickerham DL et al (2008) Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial. J Clin Oncol 26:1965–1971.  https://doi.org/10.1200/JCO.2007.14.0228 CrossRefGoogle Scholar
  9. 9.
    Jin H, Tu D, Zhao N et al (2012) Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover. J Clin Oncol 30:718–721.  https://doi.org/10.1200/JCO.2010.34.4010 CrossRefGoogle Scholar
  10. 10.
    Henry NL, Azzouz F, Desta Z et al (2012) Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 30:936–942.  https://doi.org/10.1200/JCO.2011.38.0261 CrossRefGoogle Scholar
  11. 11.
    Aiello Bowles EJ, Boudreau DM, Chubak J et al (2012) Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer. J Oncol Pract 8:e149–e157.  https://doi.org/10.1200/JOP.2012.000543 CrossRefGoogle Scholar
  12. 12.
    Crew KD, Greenlee H, Capodice J et al (2007) Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 25:3877–3883.  https://doi.org/10.1200/JCO.2007.10.7573 CrossRefGoogle Scholar
  13. 13.
    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Dowsett M, Forbes JF et al (2015) Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386:1341–1352.  https://doi.org/10.1016/S0140-6736(15)61074-1 CrossRefGoogle Scholar
  14. 14.
    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies C, Godwin J et al (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378:771–784.  https://doi.org/10.1016/S0140-6736(11)60993-8 CrossRefGoogle Scholar
  15. 15.
    Dillman DA (1978) Mail and telephone surveys. Wiley, New YorkGoogle Scholar
  16. 16.
    Rookey BD, Le L, Littlejohn M, Dillman DA (2012) Understanding the resilience of mail-back survey methods: An analysis of 20 years of change in response rates to national park surveys. Soc Sci Res 41:1404–1414.  https://doi.org/10.1016/j.ssresearch.2012.06.004 CrossRefGoogle Scholar
  17. 17.
    Sparano JA, Gray RJ, Makower DF et al (2015) Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 373:2005–2014.  https://doi.org/10.1056/NEJMoa1510764 CrossRefGoogle Scholar
  18. 18.
    Horne R, Weinman J, Hankins M (1999) The beliefs about medicines questionnaire: The development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 14:1–24.  https://doi.org/10.1080/08870449908407311 CrossRefGoogle Scholar
  19. 19.
    Corter AL, Findlay M, Broom R et al (2013) Beliefs about medicine and illness are associated with fear of cancer recurrence in women taking adjuvant endocrine therapy for breast cancer. Br J Health Psychol 18:168–181.  https://doi.org/10.1111/bjhp.12003 CrossRefGoogle Scholar
  20. 20.
    Emilsson M, Berndtsson I, Lötvall J et al (2011) The influence of personality traits and beliefs about medicines on adherence to asthma treatment. Prim Care Respir J 20:141–147.  https://doi.org/10.4104/pcrj.2011.00005 CrossRefGoogle Scholar
  21. 21.
    Horne R, Weinman J (1999) Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 47:555–567CrossRefGoogle Scholar
  22. 22.
    McQueen A, Swank PR, Bastian LA, Vernon SW (2008) Predictors of perceived susceptibility of breast cancer and changes over time: a mixed modeling approach. Heal Psychol 27:68–77.  https://doi.org/10.1037/0278-6133.27.1.68 CrossRefGoogle Scholar
  23. 23.
    Rakovitch E, Franssen E, Kim J et al (2003) A comparison of risk perception and psychological morbidity in women with ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res Treat 77:285–293CrossRefGoogle Scholar
  24. 24.
    Gotay CC, Pagano IS (2007) Assessment of Survivor Concerns (ASC): a newly proposed brief questionnaire. Health Qual Life Outcomes 5:15.  https://doi.org/10.1186/1477-7525-5-15 CrossRefGoogle Scholar
  25. 25.
    Stafford L, Judd F, Gibson P et al (2014) Comparison of the hospital anxiety and depression scale and the center for epidemiological Studies Depression Scale for detecting depression in women with breast or gynecologic cancer. Gen Hosp Psychiatry 36:74–80.  https://doi.org/10.1016/j.genhosppsych.2013.08.010 CrossRefGoogle Scholar
  26. 26.
    Fallowfield LJ, Leaity SK, Howell A et al (1999) Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Res Treat 55:189–199CrossRefGoogle Scholar
  27. 27.
    Collins ED, Moore CP, Clay KF et al (2009) Can women with early-stage breast cancer make an informed decision for mastectomy? J Clin Oncol 27:519–525.  https://doi.org/10.1200/JCO.2008.16.6215 CrossRefGoogle Scholar
  28. 28.
    Zdenkowski N, Butow P, Tesson S, Boyle F (2016) A systematic review of decision aids for patients making a decision about treatment for early breast cancer. Breast 26:31–45.  https://doi.org/10.1016/j.breast.2015.12.007 CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Kunal C. Kadakia
    • 1
  • Kelley M. Kidwell
    • 2
  • Debra L. Barton
    • 3
  • Anne F. Schott
    • 4
  • Daniel F. Hayes
    • 4
  • Jennifer J. Griggs
    • 4
  • N. Lynn Henry
    • 5
    Email author
  1. 1.Department of Solid Tumor Oncology, Levine Cancer InstituteAtrium HealthCharlotteUSA
  2. 2.Department of BiostatisticsUniversity of Michigan School of Public HealthAnn ArborUSA
  3. 3.School of NursingUniversity of MichiganAnn ArborUSA
  4. 4.Breast Oncology ProgramUniversity of Michigan Rogel Cancer CenterAnn ArborUSA
  5. 5.Division of Oncology, Huntsman Cancer InstituteUniversity of UtahSalt Lake CityUSA

Personalised recommendations